Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis

被引:14
作者
Ji, Kun [1 ]
Ma, Jianling [1 ]
Wang, Liangmin [1 ]
Li, Niuniu [1 ]
Dong, Shangjuan [1 ]
Shi, Liqing [1 ]
机构
[1] Beijing Univ Tradit Chinese Med, Dongfang Hosp, Dept Resp Med, Beijing 100078, Peoples R China
基金
中国国家自然科学基金;
关键词
EPIDEMIOLOGY; SURVIVAL; TRIAL;
D O I
10.1155/2020/1752387
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective. To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis. Methods. Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Library, ClinicalTrials, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chin VIP Information (VIP), and Chinese Biomedical Database (CBM) until December 2018. Standard mean difference (SMD) and 95% CI were calculated for the measurements related to lung function (FEV1/FVC, FVC%, FEV1%, TLC%, DLCO% or DLCO, and VC%) and other parameters (PO2, 6MWD, and SGRQ) when comparing TCM treatment to the control group. Relative risk (RR) and 95% CI of adverse events (AEs) were calculated to assess the safety of TCM. Results. A total of 40 RCTs comparing TCM to western medicine (WM) and involving 3194 IPF patients were eligible for the meta-analysis. The pooled results showed that TCM treatment improved significantly PO2 (SMD = 0.80, 95% CI 0.54 to 1.06, p < 0.001), FEV1% (SMD = 0.57, 95% CI 0.42 to 0.71, p < 0.001), DLCO% (SMD = 0.38, 95% CI 0.28 to 0.48, p < 0.001), 6MWD (SMD = 0.70, 95% CI 0.56 to 0.84, p < 0.001) and other measurements and reduced SGRQ scores (SMD = - 0.51, 95% CI - 0.70 to - 0.22, p < 0.001). Subgroup analysis of different study durations (3 months, >= 6 months) and comparison models (TCM vs. WM, TCM+ WM vs. WM or TCM vs. placebo) showed similar results. No significant difference of risk of AEs was observed between both groups (RR = 0.66, 95% CI: 0.27-1.60, p = 0.352). *ere was no obvious publication bias, and the pooled results were stable according to sensitivity analysis. Conclusion. To the best of our knowledge, the present study had the largest sample size. Our results indicated that TCM treatment may help provide benefit to the lung function, exercise capacity, and quality of life of IPF patients, alone or combined with WM, when compared to WM. More rigorous RCTs were needed in the future.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] The efficacy and safety of pirfenidone in the treatment of HPS-related pulmonary fibrosis and Idiopathic pulmonary fibrosis: a systematic review and meta-analysis
    Ma, Y. -J.
    Zhang, Q.
    Wang, C. -X.
    Wu, W.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (22) : 8411 - 8424
  • [2] Efficacy and safety of traditional chinese medicine treatment for overweight and obese individuals: A systematic review and meta-analysis
    Wen, Zhi Ge
    Zhang, Qi Qi
    Zhang, Li Li
    Shen, Meng Fei
    Huang, Yi Shan
    Zhao, Lin Hua
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Smoking and Idiopathic Pulmonary Fibrosis: A Meta-analysis
    Fang, Min
    He, Bixiu
    Xiao, Jian
    [J]. NICOTINE & TOBACCO RESEARCH, 2024, 26 (12) : 1599 - 1606
  • [4] Efficacy and safety of traditional Chinese medicine on thromboembolic events in patients with atrial fibrillation: A systematic review and meta-analysis
    Wang, Zhangsheng
    Tang, Zeng
    Zhu, Wenqing
    Ge, Lei
    Ge, Junbo
    [J]. COMPLEMENTARY THERAPIES IN MEDICINE, 2017, 32 : 1 - 10
  • [5] Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis
    Yoon, Hee-Young
    Kim, Dong Soon
    Song, Jin Woo
    [J]. RESPIRATION, 2019, 97 (03) : 242 - 251
  • [6] The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review
    Zang, Chenchen
    Zheng, Yan
    Wang, Yanqing
    Li, Lisha
    [J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2021, 26 (01)
  • [7] Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
    Zhang, Xiu-Li
    Cao, Ying
    Zheng, Bo
    [J]. BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [8] Meta-analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis
    Methot, David Bedard
    Leblanc, Evelyne
    Lacasse, Yves
    [J]. CHEST, 2019, 155 (01) : 33 - 43
  • [9] Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
    Aravena, Carlos
    Labarca, Gonzalo
    Venegas, Carmen
    Arenas, Alex
    Rada, Gabriel
    [J]. PLOS ONE, 2015, 10 (08):
  • [10] Efficacy and safety of macitentan for pulmonary hypertension: A meta-analysis
    Du, Dan
    Yuan, Ya-Dong
    [J]. CLINICAL RESPIRATORY JOURNAL, 2023, 17 (11) : 1117 - 1129